Health and Healthcare

J&J, Pfizer Halt Development of Alzheimer’s Drug

Johnson & Johnson Inc. (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimer’s after the drug failed a second clinical trial. The companies both noted the…

By 247sam
Published August 6, 2012, 5:44pm ET · 1 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Johnson & Johnson Inc. (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimer’s after the drug failed a second clinical trial.

The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.

Johnson & Johnson will take a $300 million to $400 million charge in the third quarter.

Shares of Pfizer are down 2.51% in after-hours trading. Shares of Johnson & Johnson are up 0.21%.

Samuel Weigley

Contact [email protected] for any questions or corrections.

*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term.

Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.

247sam
All articles →